Published Online
on August 9, 2004

A more recent version of this article appeared on August 24, 2004

This Article Full Text (PDF) All Versions of this Article: 110/8/1006    most recent 01.CIR.0000139335.04152.F3v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bahlmann, F. H. Articles by Fliser, D. Search for Related Content PubMed PubMed Citation Articles by Bahlmann, F. H. Articles by Fliser, D. Pubmed/NCBI databases Substance via MeSH Related Collections Animal models of human disease Apoptosis Other hypertension Endothelium/vascular type/nitric oxide Other Vascular biology

Submitted on December 16, 2003
Revised on May 13, 2004
Accepted on May 19, 2004

Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure

Ferdinand H. Bahlmann MD^*, Rong Song MD, Sascha M. Boehm MS, Michael Mengel MD, Reinhard von Wasielewski MD, Carsten Lindschau PhD, Torsten Kirsch PhD, Kirsten de Groot MD, Robert Laudeley BS, Eva Niemczyk BS, Faikah Güler MD, Jan Menne MD, Hermann Haller MD, and Danilo Fliser MD

From the Division of Nephrology, Department of Internal Medicine (F.H.B., R.S., S.M.B., C.L., T.K., K.d.G., F.G., H.H., D.F.), and Institute of Pathology (M.M., R.v.W.), Hannover Medical School; and Phenos GmbH (R.L., E.N., J.M.), Hannover, Germany.

^* To whom correspondence should be addressed. E-mail: Bahlmann.Ferdinand{at}MH-Hannover.de.

Background--The hematopoietic cytokine erythropoietin has cytoprotective effects in endothelial cells in vitro that are mediated through direct activation of the pro-survival Akt tyrosine kinase signaling pathway. We tested the hypothesis that low-dose therapy with the long-acting recombinant human erythropoietin analogue darbepoetin alpha protects vascular endothelium in vivo in a classic remnant kidney rat model characterized by severe endothelial damage, progressive vascular sclerosis, and ischemia-induced tissue fibrosis.

Methods and Results--Using a parallel group study design, we randomly assigned animals after 5/6 nephrectomy to treatment with either saline (n=36) or 0.1 µg/kg body wt darbepoetin (n=24) subcutaneously once weekly. We monitored hematocrit, blood pressure, and serum creatinine regularly and obtained renal tissue 6 weeks after nephrectomy for morphological and immunohistochemical analysis. Darbepoetin-treated animals had significantly improved survival compared with saline-treated controls (63% versus 33%; P<0.05), although hematocrit levels were similar in both groups. Darbepoetin treatment ameliorated endothelial damage; attenuated the composite tissue injury score (saline 1.9±0.4; darbepoetin 0.4±0.2; P<0.001), which included vascular sclerosis, glomerulosclerosis, and tubulointerstitial damage; and preserved renal function. We found persistent activation of the pro-survival Akt signaling pathway in endothelial and epithelial glomerular cells in darbepoetin-treated animals, accompanied by a significant reduction of apoptotic cell death in renal tissue.

Conclusions--Low-dose darbepoetin treatment confers vascular and tissue protection that is associated with persistent stimulation of the pro-survival Akt signaling pathway. The use of recombinant human erythropoietin or analogues may have utility in preventing ischemia-related progressive vascular injury and organ failure.

Key words: apoptosis • erythropoietin • tissue • vasculature • endothelium

This article has been cited by other articles:

				J. Wilflingseder, A. Kainz, P. Perco, R. Korbely, B. Mayer, and R. Oberbauer Molecular predictors for anaemia after kidney transplantation Nephrol. Dial. Transplant., March 1, 2009; 24(3): 1015 - 1023. [Abstract] [Full Text] [PDF]

				S. Ohtomo, M. Nangaku, Y. Izuhara, S. Takizawa, C. v. Y. d. Strihou, and T. Miyata Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1166 - 1172. [Abstract] [Full Text] [PDF]

				L. A Calo, P. A Davis, E. Pagnin, L. Bertipaglia, A. Naso, A. Piccoli, R. Corradini, M. Spinello, V. Savica, and L. D. Libera Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in humans and in an animal model Nephrol. Dial. Transplant., March 1, 2008; 23(3): 890 - 895. [Abstract] [Full Text] [PDF]

				E. Lipsic, B. D. Westenbrink, P. van der Meer, P. van der Harst, A. A. Voors, D. J. van Veldhuisen, R. G. Schoemaker, and W. H. van Gilst Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail, January 1, 2008; 10(1): 22 - 29. [Abstract] [Full Text] [PDF]

				B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization Eur. Heart J., August 2, 2007; 28(16): 2018 - 2027. [Abstract] [Full Text] [PDF]

				M. S. Lee, J. S. Lee, and J. Y. Lee Prevention of Erythropoietin-Associated Hypertension Hypertension, August 1, 2007; 50(2): 439 - 445. [Abstract] [Full Text] [PDF]

				J. Menne, J.-K. Park, N. Shushakova, M. Mengel, M. Meier, and D. Fliser The Continuous Erythropoietin Receptor Activator Affects Different Pathways of Diabetic Renal Injury J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2046 - 2053. [Abstract] [Full Text] [PDF]

				W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26. [Full Text] [PDF]

				E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]

				P. van der Meer and E. Lipsic Erythropoietin: Repair of the Failing Heart J. Am. Coll. Cardiol., July 4, 2006; 48(1): 185 - 186. [Full Text] [PDF]

				J. Wang, M. P. Biju, M.-H. Wang, V. H. Haase, and Z. Dong Cytoprotective Effects of Hypoxia against Cisplatin-Induced Tubular Cell Apoptosis: Involvement of Mitochondrial Inhibition and p53 Suppression J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1875 - 1885. [Abstract] [Full Text] [PDF]

				A. V. R. Santhanam, L. A. Smith, M. Akiyama, A. G. Rosales, K. R. Bailey, and Z. S. Katusic Role of Endothelial NO Synthase Phosphorylation in Cerebrovascular Protective Effect of Recombinant Erythropoietin During Subarachnoid Hemorrhage- Induced Cerebral Vasospasm Stroke, December 1, 2005; 36(12): 2731 - 2737. [Abstract] [Full Text] [PDF]

				P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133. [Abstract] [Full Text] [PDF]